Psychedelic stocks surge after Trump fast-tracks research order

Shares of biotech firms developing psychedelic-assisted therapies jumped after President Donald Trump signed an executive order on April 18, 2026 directing federal agencies to accelerate research and patient access for certain psychedelics. The move specifically named ibogaine among compounds targeted for expedited study and regulatory attention.

The order instructs the Food and Drug Administration to award three national priority review vouchers for qualifying psychedelic programs and directs $50 million in federal support toward state-led research initiatives for psychedelics. Administration officials said the measure could shrink typical FDA review timelines from many months to a matter of weeks for programs that meet national priorities, and also called for clearer pathways for patient access and potential rescheduling of approved drugs.

Market reaction was pronounced: companies such as AtaiBeckley, Compass Pathways, GH Research, Definium Therapeutics and Enveric Biosciences recorded strong premarket and opening gains, with several names rising double digits. Observers linked the rally to a perceived reduction in regulatory risk and a clearer route to commercialization for psychedelics. Jefferies analyst Andrew Tsai described the executive order as an “official stamp of validation” that should reassure investors about the administration’s support.

Despite the investor enthusiasm, scientific and safety concerns remain central. Experts note that some compounds, particularly ibogaine, have known cardiovascular risks that previously limited U.S. research; clinicians and regulators have cautioned that expedited pathways must still rely on robust safety data. The balance between faster access and thorough risk evaluation will shape both clinical programs and long-term investor sentiment.

Analysts say the executive order could lift investor interest in the sector through 2027–2030 if clinical readouts and regulatory milestones progress as hoped, but they also warn of persistent volatility. Key near-term catalysts to watch include which programs receive the FDA’s priority vouchers, the start and results of any U.S. ibogaine trials, and subsequent FDA and DEA actions on scheduling and patient-access policies.